Tarsus Pharmaceuticals, Inc. TARS
76.00 USD +2.17 (+2.94%)
Nov 11, 2026, 9:57 AM EST
73.60 Day range 76.18
53.89 52-week range 91.53
- YTD
- -7.18%
- 1 year
- +0.48%
News
globenewswire.com Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.
benzinga.com HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $106 HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $106.
benzinga.com UPDATE: Tarsus Pharmaceuticals Q3 Adj. EPS $(0.78) Beats $(2.73) Estimate, Sales $194.569M Beat $186.598M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(2.73) by 71.43 percent. This is a 160 percent decrease over losses…
benzinga.com Tarsus Pharmaceuticals Q3 2026 Earnings Call Transcript Tarsus Pharmaceuticals (NASDAQ:TARS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.
benzinga.com Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.
benzinga.com Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105 Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.
benzinga.com Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and…
benzinga.com Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100 Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.- benzinga.com Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses…
- benzinga.com Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not Disclosed Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of…
- benzinga.com Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98 Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.
- benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89 Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $90 to $89.
benzinga.com Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the deal a disciplined pipeline expansion.- benzinga.com HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
- benzinga.com Tarsus Acquires iRenix Medical And Late-Stage Asset IRX-101 For ~$75M IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of carePositive Phase 2b/3 data and an FDA-aligned Phase 3 program provide…
benzinga.com Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal…- benzinga.com Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
- benzinga.com Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs – A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals,…
- benzinga.com Tarsus Pharmaceuticals Announces $15M Milestone Payment Achieved After Regulatory Approval Of TP-03 By China's National Medical Products Administration Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution)…
- benzinga.com Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105 Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $95 to $105.
- benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.
benzinga.com Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday - benzinga.com Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over…
benzinga.com Insights into Tarsus Pharmaceuticals Q4 Earnings - benzinga.com Earnings Scheduled For February 23, 2026
benzinga.com Earnings Preview: Tarsus Pharmaceuticals 
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Earnings Scheduled For May 1, 2025
benzinga.com Earnings Scheduled For February 25, 2025 - benzinga.com Earnings Scheduled For November 13, 2024
benzinga.com Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - benzinga.com Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported…
- benzinga.com Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.
- benzinga.com Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported…
- benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 211 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's morning trading, 152 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's session saw 466 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday During Thursday's morning session, 316 companies made new 52-week highs.